CLINICAL TRIALS PROFILE FOR IOFLUPANE I-123

All Clinical Trials for ioflupane i-123

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01141023 ↗	Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression	Active, not recruiting	Institute for Neurodegenerative Disorders	Phase 2	2010-06-01	This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
NCT01141023 ↗	Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression	Active, not recruiting	Ken Marek, MD	Phase 2	2010-06-01	This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
NCT01453127 ↗	DaTSCAN Imaging in Aging and Neurodegenerative Disease	Enrolling by invitation	Mayo Clinic	Phase 4	2011-10-01	The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.
NCT03185182 ↗	Diagnostic Imaging for Clear Cell Renal Cell Carcinoma	Terminated	Lund University	Phase 2	2017-07-14	The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
NCT03185182 ↗	Diagnostic Imaging for Clear Cell Renal Cell Carcinoma	Terminated	Region Skane	Phase 2	2017-07-14	The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype.
NCT03582488 ↗	Longitudinal Imaging Biomarkers of Disease Progression in DLB	Enrolling by invitation	Kejal Kantarci	Phase 4	2018-06-25	The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline.

Clinical Trial Conditions for ioflupane i-123

Condition Name

Condition Name for ioflupane i-123
Intervention	Trials
REM Sleep Behavior Disorder	3
Symptomatic Parkinson Disease	2
Pre-motor Parkinson Disease	2
Dementia	1

Condition MeSH

Condition MeSH for ioflupane i-123
Intervention	Trials
Parkinson Disease	4
Mental Disorders	3
REM Sleep Behavior Disorder	3
Parkinsonian Disorders	2

Clinical Trial Locations for ioflupane i-123

Trials by Country

Trials by Country for ioflupane i-123
Location	Trials
United States	20
China	7
Australia	1
Germany	1
Italy	1

Trials by US State

Trials by US State for ioflupane i-123
Location	Trials
California	3
Minnesota	2
Florida	2
Connecticut	1
Arizona	1

Clinical Trial Progress for ioflupane i-123

Clinical Trial Phase

Clinical Trial Phase for ioflupane i-123
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for ioflupane i-123
Clinical Trial Phase	Trials
Enrolling by invitation	3
Recruiting	2
Active, not recruiting	1

Clinical Trial Sponsors for ioflupane i-123

Sponsor Name

Sponsor Name for ioflupane i-123
Sponsor	Trials
PPD	2
GE Healthcare	2
Institute for Neurodegenerative Disorders	1

Sponsor Type

Sponsor Type for ioflupane i-123
Sponsor	Trials
Other	8
Industry	4